| Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer J Brägelmann, N Klümper, A Offermann, A Von Maessenhausen, D Böhm, ... Clinical Cancer Research 23 (7), 1829-1840, 2017 | 97 | 2017 |
| LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma N Klümper, DJ Ralser, EG Bawden, J Landsberg, R Zarbl, G Kristiansen, ... Journal for ImmunoTherapy of cancer 8 (1), 2020 | 82 | 2020 |
| Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma S Schrödter, M Braun, I Syring, N Klümper, M Deng, D Schmidt, S Perner, ... Molecular cancer 15, 1-10, 2016 | 72 | 2016 |
| The N6‐methyladenosine (m6A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity‐associated protein (FTO) are prognostic biomarkers … A Strick, F von Hagen, L Gundert, N Klümper, Y Tolkach, D Schmidt, ... BJU international 125 (4), 617-624, 2020 | 68 | 2020 |
| Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance N Klümper, DJ Ralser, J Ellinger, F Roghmann, J Albrecht, E Below, ... Clinical Cancer Research 29 (8), 1496-1505, 2023 | 61 | 2023 |
| Systematic analysis of the expression of the mitochondrial ATP synthase (complex V) subunits in clear cell renal cell carcinoma M Brüggemann, A Gromes, M Poss, D Schmidt, N Klümper, Y Tolkach, ... Translational oncology 10 (4), 661-668, 2017 | 54 | 2017 |
| C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer N Klümper, J Saal, F Berner, C Lichtensteiger, N Wyss, A Heine, ... Journal for Immunotherapy of Cancer 10 (3), 2022 | 49 | 2022 |
| Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors NG Nunez, F Berner, E Friebel, S Unger, N Wyss, JM Gomez, MT Purde, ... Med 4 (2), 113-129. e7, 2023 | 42 | 2023 |
| MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy S Laban, G Giebel, N Klümper, A Schröck, J Doescher, G Spagnoli, ... Oncotarget 8 (9), 14719, 2017 | 32 | 2017 |
| Cultivation of clear cell renal cell carcinoma patient-derived organoids in an air-liquid interface system as a tool for studying individualized therapy LK Esser, V Branchi, S Leonardelli, N Pelusi, AG Simon, N Klümper, ... Frontiers in oncology 10, 1775, 2020 | 30 | 2020 |
| CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear … N Klümper, DJ Ralser, R Zarbl, K Schlack, AJ Schrader, M Rehlinghaus, ... Journal for Immunotherapy of Cancer 9 (8), 2021 | 28 | 2021 |
| Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types I Syring, N Klümper, A Offermann, M Braun, M Deng, D Boehm, ... Oncotarget 7 (17), 23043, 2016 | 27 | 2016 |
| NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival FE Müller, M Braun, I Syring, N Klümper, D Schmidt, S Perner, S Hauser, ... American journal of cancer research 5 (9), 2816, 2015 | 25 | 2015 |
| The Cdkn1aSUPER mouse as a tool to study p53-mediated tumor suppression A Torgovnick, JM Heger, V Liaki, J Isensee, A Schmitt, G Knittel, ... Cell reports 25 (4), 1027-1039. e6, 2018 | 22 | 2018 |
| Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade F Berner, D Bomze, C Lichtensteiger, V Walter, R Niederer, O Hasan Ali, ... Science immunology 7 (75), eabn9644, 2022 | 20 | 2022 |
| N6‐Methyladenosine (m6A) readers are dysregulated in renal cell carcinoma F von Hagen, L Gundert, A Strick, N Klümper, D Schmidt, G Kristiansen, ... Molecular Carcinogenesis 60 (5), 354-362, 2021 | 20 | 2021 |
| C-reactive protein flare predicts response to anti-PD-(L) 1 immune checkpoint blockade in metastatic urothelial carcinoma N Klümper, D Sikic, J Saal, T Büttner, F Goldschmidt, J Jarczyk, P Becker, ... European Journal of Cancer 167, 13-22, 2022 | 19 | 2022 |
| CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma L Frey, N Klümper, D Schmidt, G Kristiansen, M Toma, M Ritter, A Alajati, ... Cancers 13 (9), 2177, 2021 | 18 | 2021 |
| C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma N Klümper, P Schmucker, O Hahn, B Höh, A Mattigk, S Banek, J Ellinger, ... Clinical & Translational Immunology 10 (12), e1358, 2021 | 18 | 2021 |
| Ercc1 deficiency promotes tumorigenesis and increases cisplatin sensitivity in a TP53 context-specific manner M Jokić, I Vlašić, M Rinneburger, N Klümper, J Spiro, W Vogel, ... Molecular Cancer Research 14 (11), 1110-1123, 2016 | 18 | 2016 |
